ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
"We are proud to announce another step for our Company in introducing thepain relief and healing benefits of ActiPatch to the international market. Weare working closely with Distinction Corporation and excited to include themin our growing list of distributors. I have every confidence that this newrelationship will bring not only success to our two companies in the Kingdomof Jordan, but also additional expansion into other Middles East markets,"said Andrew Whelan, President of BioElectronics Corporation.
Farid Tamini, President of Distinction Corporation, said, "With theapproval process behind us, we will quickly launch this wonderful product inthe Kingdom of Jordan. We are pleased to be working with BioElectronics.There is an air of enthusiasm for this unique drug free therapy that willsurely multiply as the medical professionals and patients experience thebenefits of ActiPatch."
BioElectronics Corporation is the maker of ActiPatch. ActiPatch is adrug-free anti-inflammatory patch with an embedded battery operated microchipthat delivers weeks of continuous pulsed therapy for less than a dollar a day.The unique ActiPatch delivery system, using patented technology, provides acost-effective, patient friendly method to reduce soft tissue pain andswelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to futuregrowth and earnings opportunities. Such statements are based upon certainassumptions and assessments made by management of both companies in light ofcurrent conditions, expected future developments and other factors it believesto be appropriate. Actual results may differ as a result of factors over whichthe companies have no control.
SOURCE BioElectronics Corporation
You May Also Like